Patents Assigned to ZymoGenetics
  • Compositions and methods for treating bone deficit conditions
    Patent number: 6342514
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or “linker” defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 Å, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: January 29, 2002
    Assignees: ZymoGenetics, Inc., Osteoscreen, Inc.
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Maria Kontoyianni, Gregory R. Mundy
  • Secreted salivary ZSIG63 Polypeptide
    Patent number: 6331413
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig63, a novel secreted salivary protein. The polypeptides, and polynucleotides encoding them, may exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The polynucleotides encoding zsig63, are located on chromosome 4, and can be used to identify a region of the genome associated with human disease states. The present invention also includes antibodies to the zsig63 polypeptides.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: December 18, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: David A. Adler, Paul O. Sheppard
  • Interferon-&egr;
    Patent number: 6329175
    Abstract: Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. To date, four types of interferons have been found in humans: interferon-&agr;, interferon-&bgr;, interferon-&ggr;, and interferon-&ohgr;. The present invention provides new forms of human and murine interferon, “interferon-&egr;,” which have applications in diagnosis and therapy.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: December 11, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Francis J. Grant, Mark W. Rixon, Wayne Kindsvogel
  • Ligand-binding, dimerized polypeptide fusions
    Patent number: 6323323
    Abstract: Ligand-binding, dimerized polypeptide fusions comprising two polypeptide chains are disclosed. Each of the polypeptide chains comprises a ligand-binding domain of either a growth factor receptor or a hormone receptor joined to an immunoglobulin constant region polypeptide. Dimerization of the polypeptide fusion results in enhancement of biological activity. The immunoglobulin constant region polypeptide may comprise an immunoglobulin heavy chain constant region domain and hinge region.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: November 27, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrzej Z. Sledziewski, Lillian Anne Bell, Wayne R. Kindsvogel
  • Motilin homologs
    Publication number: 20010041791
    Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
    Type: Application
    Filed: February 27, 2001
    Publication date: November 15, 2001
    Applicant: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher, Paul D. Bishop, Stephen R. Jaspers, Virender M. Labroo
  • Protection against ischemia and reperfusion injury
    Patent number: 6316411
    Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.
    Type: Grant
    Filed: January 4, 2000
    Date of Patent: November 13, 2001
    Assignees: University of Kentucky Research Foundation, ZymoGenetics
    Inventors: Peter R. Oeltgen, Paul D. Bishop, Mark S. Kindy, Juan A. Sanchez
  • Murine interferon-&agr;
    Patent number: 6312924
    Abstract: Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. The present invention provides a new form of murine interferon-&agr;, which has applications in diagnosis and therapy.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: November 6, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Andrew L. Feldhaus, Zeren Gao
  • Cytokine zalpha11 Ligand
    Patent number: 6307024
    Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: March 9, 2000
    Date of Patent: October 23, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Nucleic acids encoding mammalian alpha helical protein-1
    Patent number: 6303770
    Abstract: Novel mammalian alpha helical polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: October 16, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Si Lok, Darrell C. Conklin, Julia E. Parrish
  • Islet cell antigen 1851
    Patent number: 6300093
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: October 9, 2001
    Assignees: ZymoGenetics, Inc., University of Washington
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Methods for producing secreted ligand-binding fusion proteins
    Patent number: 6300099
    Abstract: Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
    Type: Grant
    Filed: May 30, 2000
    Date of Patent: October 9, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrzej Z. Sledziewski, Lillian Anne Bell, Wayne R. Kindsvogel
  • Method for treating ischemia
    Patent number: 6294519
    Abstract: A method for treating ischemia by administering deltorphins to a mammal. Deltorphin I SEQ ID NO:1, delntorphin II SEQ ID NO:2 or combinations of deltorphins I SEQ ID NO:1 and II SEQ ID NO:2 may be administered. A deltorphin concentration of about 0.5-20 mg/kg body weight, or alternatively a lower concentration of about 1-1000 &mgr;g/kg body weight of the mammal in a physiologically acceptable formulation is administered up to four hours after an ischemic episode. Deltorphins may also be administered prior to or concurrently with onset of ischemia. Cerebral or spinal cord ischemia or ischemic heart disease may be treated using the method of the invention.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: September 25, 2001
    Assignees: University of Kentucky Research Foundation, ZymoGenetics
    Inventors: Peter R. Oeltgen, Mark S. Kindy, Paul D. Bishop
  • DNA constructs encoding ligand-binding fusion proteins
    Patent number: 6291212
    Abstract: Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
    Type: Grant
    Filed: May 30, 2000
    Date of Patent: September 18, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrzej Z. Sledziewski, Lillian Anne Bell, Wayne R. Kindsvogel
  • Dimerized polypeptide fusions
    Patent number: 6291646
    Abstract: Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
    Type: Grant
    Filed: May 30, 2000
    Date of Patent: September 18, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrzej Z. Sledziewski, Lillian Anne Bell, Wayne R. Kindsvogel
  • Antibodies to motilin homologs
    Patent number: 6291653
    Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: September 18, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher
  • Zace 1: a human metalloenzyme
    Patent number: 6280994
    Abstract: Angiotensin-converting enzyme is a zinc metallopeptidase that plays roles in blood pressure regulation and fertility. The catalytic activities of angiotensin converting enzymes include the production of the potent vasopressor angiotensin II from angiotensin I, and the inactivation of the vasodilatory peptide bradykinin. Zace1 is a new form of human zinc metallopeptidase, which includes one zinc-dependent catalytic domain containing the motif “HEXXH” and one downstream “EX(I/V)X(D/S)” motif.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: August 28, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • L-AP4 sensitive glutamate receptors
    Patent number: 6274330
    Abstract: Metabotropic receptor mGluR7 is identified and sequenced. The mGluR7 receptor subfamily mediates inhibition of transmitter release at selected glutamatergic synapses. The receptors, mGluR7-specific peptides and antibodies thereto are used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal transmitter release, as well as in methods of diagnosis and therapy.
    Type: Grant
    Filed: December 30, 1993
    Date of Patent: August 14, 2001
    Assignees: ZymoGenetics, Inc., State of Oregon, acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University
    Inventors: Thomas P. Segerson, J. Mark Kinzie, Eileen R. Mulvihill, Julie A. Saugstad, Gary L. Westbrook
  • Mammalian cytokine-like receptor 5
    Patent number: 6271343
    Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions. The polypeptides of the present invention can be used to down-regulate their natural ligands. The polynucleotides and subsequences thereof can be used as diagnostic probes to determine if chromosome 19 is mutated. The antibodies which bind to the polypeptides can be used to purify the receptors and to inhibit the binding of the ligands onto the receptors.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: August 7, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Si Lok, Scott R. Presnell, Anna C. Jelmberg, Teresa Gilbert, Theodore E. Whitmore, Donald C. Foster, Robyn L. Adams, Joyce M. Lehner
  • Piperazine derivatives for treating bone deficit conditions
    Patent number: 6268367
    Abstract: Piperazine derivatives useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disorder, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery and post-dental implantation.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: July 31, 2001
    Assignee: Zymogenetics, Inc.
    Inventor: James R. Piggott
  • Disintegrin homologs
    Patent number: 6265199
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zdint1, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are believed to be cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the zdint 1 polypeptides.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: July 24, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Nand Baindur, Theresa A. Deisher, Paul D. Bishop, David W. Taft